Bansal N, Mims J, Kuremsky JG, Olex AL, Zhao W, Yin L, Wani R, Qian J, Center B, Marrs GS, Porosnicu M, Fetrow JS, Tsang AW, Furdui CM. Broad phenotypic changes associated with gain of radiation resistance in head and neck squamous cell cancer
. Antioxid Redox Signal. 2014;21(2):221-236.
Vatca M, Lucas JT Jr, Laudadio J, D'Agostino RB, Waltonen JD, Sullivan CA, Rouchard-Plasser R, Matsangou M, Browne JD, Greven KM, Porosnicu M. Retrospective analysis of the impact of HPV status and smoking on mucositis in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemotherapy and radiotherapy
. Oral Oncol. 2014;50(9):869-876.
Lucas JT, Porosnicu M, Plasser R, Sullivan CA, Waltonen JD, Brown JD, Greven KM. Phase 1/2 clinical trial of re-irradiation with pemetrexed and erlotinib followed by maintenance erlotinib for recurrent and second primary squamous cell carcinoma of the head and neck (SCCHN) [abstract]. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S179.
Garg S, Kilburn JM, Randolph DM, Lucas JT, Urbanic JJ, Porosnicu M, Hinson WH, Kearns WT, Greven KM. Re-irradiation for second primary or recurrent cancers of the head and neck: composite dosimetric measures to evaluate dose to the carotid arteries [abstract]. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S480-S481.
Porosnicu M, Liu J, Lyles D. Susceptibility of head and neck cancer to an attenuated model of the oncolytic vesicular stomatitis virus expressing suicide genes [abstract]. J Clin Oncol. 2010;27(15 Suppl):e14604.
Blackstock A, Petty J, Oaks T, Porosnicu M, Clark H, Lovato J, Miller A. Gefitinig (ZD-1839) with concurrent docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel/gefitinib for patients with stage III NSCLC: a phase I study [abstract]. J Clin Oncol. 2007;25(18 Suppl):Abstr18165.
Blackstock AW, Jensen CA, Petty WJ, Oaks T, Porosnicu M, Clark H, Lovato JF, Miller A. Gefitinib (ZD-1839) with concurrent docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel/gefitinib for patients with stage III NSCLC: a phase I study [abstract]. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S476.
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.
Assistant Professor, Hematology & Oncology
Head and Neck Cancers, Head and Neck Oncology
The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.
Gave me the good news that cancer had not returned!
They really care that I understand everything and are concerned about me as a person.